ATUM-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ATUM - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014138
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ATUM, formerly DNA2.0 Inc is a bioengineering company that provide platforms for protein and vector engineering solutions. The company develops and offers synthetic biology solutions. Its products include expression vectors, electra system, CRISPR/Cas9, proteinpaintbox, cell strains and reagents. ATUM offers services such as gene synthesis, protein engineering, expression optimization, and vector engineering. The company provides antibody to developing enzymes for commercial drug and biofuel manufacture. It provides synthetic biology tools that include gene designer, GRNA designer, DNA atlas, bioinformatic, toolbox and literature database. The company serves academic, government and the pharmaceutical, chemical, agricultural and biotechnology industries. It operates through its office located in the US and Europe. ATUM is headquartered in Newark, California, the US.

ATUM – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATUM, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
ATUM, Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Pareto Biotech Enters into Technology Integration Agreement with DNA2.0 9
DNA2.0 Enters Into Research Agreement With St George’s University Of London For Production Of Therapeutic Antibodies 10
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 11
DNA2.0 And Aldevron Enter Into Agreement For Insect Cell Expression System 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Licensing Agreements 14
ATUM Enters into Licensing Agreement with Horizon Discovery 14
Horizon Discovery Enters into Licensing Agreement with ATUM 15
Acquisition 16
DNA2.0 to Acquire MIGS 16
ATUM – Key Competitors 17
ATUM – Key Employees 18
ATUM – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Other Significant Developments 20
Apr 10, 2017: ATUM Launches Cell-Line Development Service 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
ATUM, Pharmaceuticals & Healthcare, Key Facts 2
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATUM, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Pareto Biotech Enters into Technology Integration Agreement with DNA2.0 9
DNA2.0 Enters Into Research Agreement With St George's University Of London For Production Of Therapeutic Antibodies 10
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 11
DNA2.0 And Aldevron Enter Into Agreement For Insect Cell Expression System 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
ATUM Enters into Licensing Agreement with Horizon Discovery 14
Horizon Discovery Enters into Licensing Agreement with ATUM 15
DNA2.0 to Acquire MIGS 16
ATUM, Key Competitors 17
ATUM, Key Employees 18
ATUM, Subsidiaries 19

★海外企業調査レポート[ATUM-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CLP Holdings Ltd (2)-エネルギー分野:企業M&A・提携分析
    Summary CLP Holdings Limited (CLP) is an investor and operator in the energy sector of Asia Pacific region. The company invests in power generation, transmission and distribution, and electricity and gas retail activities. Its portfolio includes equity generating and purchase capacities. CLP’s gener …
  • Ixia (XXIA):企業の財務・戦略的SWOT分析
    Summary Ixia (Ixia), a subsidiary of Keysight Technologies Inc, is a technology company that offers test architecture solutions and services. The company's products potfolio include visibility, test, cloud, security, performance monitoring, and test hardware products. Its security products comprise …
  • Smrt Corporation Ltd.
    Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PMA Companies Inc:企業の戦略・SWOT・財務分析
    PMA Companies Inc - Strategy, SWOT and Corporate Finance Report Summary PMA Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PCI Pharma Services-製薬・医療分野:企業M&A・提携分析
    Summary PCI Pharma Services (PCI) is a drug development company that offers clinical manufacturing and packaging solutions. The company offers clinical services such as pharmaceutical development, clinical trial manufacturing, clinical trial packaging, clinical supplies management, clinical planning …
  • Achelios Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Achelios Therapeutics Inc (Achelios) is a biopharmaceutical development company that provides reformulation of non-steroidal anti-inflammatory (NSAID) drug molecules. The company offers therapeutic entity development for the treatment of pain and inflammation. Its lead product includes Topof …
  • Graftobian Makeup Company:企業の戦略・SWOT・財務情報
    Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report Summary Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • University of Melbourne-医療機器分野:企業M&A・提携分析
    Summary The University of Melbourne is an educational service provider that offers graduate, postgraduate, and research degrees. The university offers education in various fields which include arts, engineering, business and economics, architecture, building and planning, land and environment, medic …
  • Canbriam Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Canbriam Energy Inc (Canbriam) is an oil and gas exploration company that offers finding and developing liquids rich natural gas resources. The company develops liquids rich natural gas resources in the Western Canadian Sedimentary Basin. It owns and operates oil and gas producing properties …
  • JMC Projects (India) Ltd (JMCPROJECT):企業の財務・戦略的SWOT分析
    JMC Projects (India) Ltd (JMCPROJECT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Copelouzos group-エネルギー分野:企業M&A・提携分析
    Summary Copelouzos group (Copelouzos) is an energy company that offers business development services. The company’s services include energy production and training, equipment supply, wastes management, natural gas, and concession and property services. It’s waste management services include residues …
  • Central National-Gottesman Inc.:企業の戦略・SWOT・財務情報
    Central National-Gottesman Inc. - Strategy, SWOT and Corporate Finance Report Summary Central National-Gottesman Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Wacker Neuson Se:企業の戦略・SWOT・財務分析
    Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report Summary Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, libromide, somulose, vetoryl, rapidexon, octacillin, domidine …
  • VT Holdings Co Ltd (7593):企業の財務・戦略的SWOT分析
    VT Holdings Co Ltd (7593) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Emerald Resources NL (EMR):企業の財務・戦略的SWOT分析
    Summary Emerald Resources NL (Emerald) is an oil and gas company that carries out mineral exploration and development. The company carries out acquisition, exploration, development and produces oil and natural gas, and gold deposits. Its projects include Okavu Gold project, and Magoffin County proje …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066):企業の財務・戦略的SWOT分析
    Shandong Weigao Group Medical Polymer Company Ltd (1066) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析
    BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mediclin AG (MED):企業の財務・戦略的SWOT分析
    Summary Mediclin AG (Mediclin) is a healthcare service provider that provides rehabilitation and medical care services. The center provides services in neuro-medicine with neurology, early neurological rehabilitation, neurosurgery and neuroradiology and psychological sciences, among others. It also …
  • Meril Life Sciences Pvt Ltd:製品パイプライン分析
    Summary Meril Life Sciences Pvt Ltd (Meril) is a medical device company that develops and designs clinically relevant devices. The company’s product categories include cardiovascular devices, vascular interventional devices, orthopedic devices, in-vitro diagnostics devices and endo-surgery devices. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆